$ News

CARMILA: Information Concerning the Total Number of Voting Rights and Share

Carmila: Information Concerning the Total Number of Voting Rights and Share

CORRECTING and REPLACING: CARMILA: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de Commerce (French Commercial Code) and Article 223-16 of the Règlement Général ...

Assessing Carmila (ENXTPA:CARM) Valuation After Recent Share Moves And Perceived Discount

CARMILA: Information Concerning the Total Number of Voting Rights and Share

Carmila Makes its 2025 Universal Registration Document Available

Liberate Bio gains licences for myeloid-specific CAR design patents

Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs

Carisma Announces Delisting from Nasdaq and SEC Deregistration

CARISMA Therapeutics Q3 EPS $1.07 Beats $(0.12) Estimate, Sales $45.250M Beat $3.771M Estimate

Carisma Therapeutics shares are trading higher after the company announced it will received a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix.

Carisma Therapeutics shares are trading higher after the company announced it will received a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix.

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $1 Price Target

Carisma Therapeutics Shares Resume Trade

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

CARISMA Therapeutics Q1 EPS $(0.22) Misses $(0.10) Estimate, Sales $3.73M Inline

Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations

Carisma Therapeutics shares are trading lower after D. Boral Capital cut its price target on the stock from $12 to $1.

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $1